Gilead Sciences, Inc.

NASDAQ:GILD  
68.55
-0.36 (-0.52%)
Products

Gilead's Magrolimab Receives FDA Breakthrough Therapy Designation

Published: 09/15/2020 13:18 GMT
Gilead Sciences, Inc. (GILD) - Gilead’s Magrolimab, an Investigational Anti-cd47 Monoclonal Antibody, Receives FDA Breakthrough Therapy Designation for Treatment of Myelodysplastic Syndrome.